J&J’s Tremfya Shows Extended Success in Treating Plaque PsoriasisAnti-IL-23 monoclonal biologic antibodies, Biologics, Blockbusters, Clinical Trials, Hidradenitis suppurativa, Immune-Mediated Diseases, Monoclonal Antibodies, Plaque Psoriasis, Psoriasis, R&D, Ulcerative ColitisJ&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study. Read more October 18, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-10-18 12:31:362019-10-18 13:40:15J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis
